EP1501794A1 - Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo - Google Patents

Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo

Info

Publication number
EP1501794A1
EP1501794A1 EP03718796A EP03718796A EP1501794A1 EP 1501794 A1 EP1501794 A1 EP 1501794A1 EP 03718796 A EP03718796 A EP 03718796A EP 03718796 A EP03718796 A EP 03718796A EP 1501794 A1 EP1501794 A1 EP 1501794A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkylene
group
hydroxy
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03718796A
Other languages
German (de)
English (en)
Inventor
Wolfgang Schwede
Volker Schulze
Knut Eis
Bernd Buchmann
Hans Briem
Gerhard Siemeister
Ulf Bömer
Karsten Parczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP1501794A1 publication Critical patent/EP1501794A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates to thiazolidones, their preparation and use as
  • Tumor cells are characterized by an unrestrained cell cycle process. This is based on the one hand on the loss of control proteins such as RB, p16, p21, p53, etc., and the activation of so-called accelerators of the cell-cycle process, the cyclin-dependent kinases (Cdk's).
  • the Cdk's are a pharmacy recognized anti-tumor target protein.
  • new cell cycle regulating serine / threonine kinases so-called ! Polo-like kinases', which are involved not only in the regulation of the cell cycle but also in the coordination with other processes during mitosis and cytokinesis (formation of spindle apparatus, chromosome separation).
  • this class of proteins provides an interesting target for the therapeutic intervention of proliferative diseases such as cancer (Descombes and Nigg. Embo J, 17, 1328ff, 1998, Glover et al., Genes Dev 12, 3777ff, 1998).
  • Plk-1 A high expression rate of Plk-1 has been reported in non-small cell lung cancer (Wolf et al Oncogene, 14, 543ff, 1997), in melanomas (Strebhardt et al., JAMA, 283, 479ff, 2000).
  • squamous cell carcinomas' Knecht et al., Cancer Res., 59, 2794ff, 1999
  • 'esophageal carcinomas' Tokumitsu et al., Int J Oncol 15, 687ff, 1999.
  • a '20 -mer 'antisense oligo inhibited the expression of Plk-1 in A549 cells and stopped their viability. Likewise, a clear anti-tumor effect could be shown in nude mice (Mundt et al., Biochem Biophys Res Comm, 269, 377ff., 2000).
  • antisense oligo molecules did not inhibit the growth and viability of primary human mesangial cells (Mundt et al., Biochem Biophys ResComm, 269, 377ff., 2000).
  • thiazolidones are suitable inhibitors of polo family kinases.
  • the sequence identity within the polypic spiking domains is between 40 and 60%, so that in part interaction of inhibitors of a kinase with one or more other kinases of this family occur.
  • the effect may also be selective or preferential on only one kinase of the polo family.
  • the compounds according to the invention essentially inhibit the polo like kinases, as well as their action against for example cancer, such as solid tumors and leukemia, autoimmune diseases such as psoriasis, alopecia, and multiple sclerosis, chemotherapeutic-induced alopecia and mucositis, cardiovascular diseases such as stenoses, arterioscleroses and restenosis, infectious diseases such.
  • cancer such as solid tumors and leukemia, autoimmune diseases such as psoriasis, alopecia, and multiple sclerosis, chemotherapeutic-induced alopecia and mucositis, cardiovascular diseases such as stenoses, arterioscleroses and restenosis, infectious diseases such.
  • cancer such as solid tumors and leukemia, autoimmune diseases such as psoriasis, alopecia, and multiple sclerosis, chemotherapeutic-induced alopecia and mucositis, cardiovascular diseases such as stenoses, arterioscleroses
  • Glomerulonephritis chronic neurodegenerative diseases such as Huntington's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease, acute neurodegenerative diseases such as brain ischaemia and neurotrauma, viral infections such as. As cytomegalovirus infections, herpes, hepatitis B and C, and HIV-based diseases.
  • the present invention thus relates to compounds of general formula I.
  • X and Y are the same or different and are hydrogen, aryl,
  • R 19 and R 20 are the same or different and are hydrogen, C
  • C ⁇ -C 6 alkyl C 3 -C 6 cycloalkyl, halo-Cr C6-alkyl, halo-Ci-C ⁇ -alkoxy, halogen, cyano, hydroxy, C ⁇ -C 6 -alkylene, hydroxy-C 1 -C 6 -alkyleneoxy, aryl, heteroaryl, heterocyclyl, -C ⁇ -C 6 alkyl COOR 8 or with the group -OR 10 , -COR 13 , -COOR 14 , -NR 11 R 12 ,
  • R 2 and R 3 , R 11 and R 12 , R 15 and R 16 and R 19 and R 20 each independently, together form a 3 to 10 membered ring optionally containing one or more nitrogen, oxygen or sulfur atoms or R 3 is hydrogen and
  • R 2 is the group - (LM) in which
  • L represents a group -C (O) -, -S (O) 2 -, -C (O) N (R 7 ) -, -S (O) 2 N (R 7 ) -,
  • -C (S) N (R 7 ) -, -C (S) N (R 7 ) C (O) O-, -C (O) O- or -C (O) S- and M is hydrogen, dC 10 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl,
  • (C 3 -C 6 cycloalkyl) C 1 -C 4 alkylene, C 3 -C 6 cycloalkyl, phenyl-C 3 - Ce-cycloalkyl, dC 10 alkanoyl, dC 4 alkoxy-C 1 -C 4 -alkylene, -CC 4 -alkoxycarbonyl-C 4 -alkylene, hydroxy-C 1 -C 0 -alkylene, or optionally mono- or polysubstituted, identical or different, with -CC 4 -alkyl, C 2 -C 6 Alkenyl, C 3 -C 6 cycloalkyl,
  • R 7 is hydrogen, dC 10 alkyl, C 2 -C 10 alkenyl, C 2 -C ⁇ 0 alkynyl, C 3 -
  • Heterocyclyl, R 22 is hydrogen, hydroxy-C 1 -C 6 -alkyl, or for the group
  • R 23 is hydrogen or C 1 -C 6 -alkyl
  • R 24 is hydrogen, phenyl, C 1 -C 6 alkoxy or the group
  • R 25 represents the group -OR 10 or optionally monosubstituted or polysubstituted, identically or differently with halogen, C 6 - alkyl, hydroxy-C ⁇ -C 6 - C 2 -C 6 alkenyl, phenyl, pyridyl, imidazolyl, morpholinyl, piperidinyl, C 3 -C 6 cycloalkyl or substituted by the group - OR 10 or -COOR 14 or
  • each of m, p, k independently of one another, is 0 or 1
  • n is 0, 1
  • q is 1 or 2 , As well as their
  • Stereoisomers mixtures of the stereoisomers and their salts, are valuable compounds for inhibiting the PLK and which can be used in the above-mentioned diseases.
  • Alkyl is in each case a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl and decyl.
  • Alkoxy is in each case a straight-chain or branched alkoxy radical, such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec. Butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy.
  • alkoxy radical such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec. Butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy.
  • alkenyl substituents are in each case straight-chain or branched, for example the following radicals being meant: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl , But-2-en-1-yl, but-2-en-2-yl, 2-methylprop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, But -1-en-3-yl, but-3-en-1-yl, allyl.
  • Alkynyl is in each case to be understood as meaning a straight-chain or branched alkynyl radical which contains 2-6, preferably 2-4, C atoms.
  • the following radicals may be mentioned as examples: acetylene, propyn-1-yl, propyn-3-yl, but-1-yn-1-yl, but-1-yn-4-yl, but-2-yn-1-yl , But-1-yn-3-yl, etc.
  • Heterocyclyl is an alkyl ring comprising 3 to 12 carbon atoms which, instead of the carbon, has one or more identical or different heteroatoms, such as, for example, B. oxygen, sulfur or nitrogen and may contain at one or more carbon or nitrogen atoms another substituent.
  • Substituents on nitrogen may be alkyl, COR 13 , -COOR 14 , -CONR 15 R 16 , -SO 2 R 18 , SO 2 NR 19 R 20 .
  • heterocyclyl z examples are: oxiranyl, oxethanyl, aziridinyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, dioxanyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, quinuclidinyl, pyrolidonyl, N-methylpyrrolidinyl, 2-hydroxymethylpyrrolidinyl, Hydroxypyrrolidinyl, N-methylpiperazinyl, N-acetylpiperazinyl, N-methylsulfonylpiperazinyl, 4-hydroxypiperidinyl, 4-aminocarbonylpiperidinyl, 2-hydroxyethylpiperidinyl, 4-hydroxymethylpiperidinyl, etc. Cycloalkyl is to
  • Cycloalkyl is to be understood as meaning monocyclic alkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, but also bicyclic rings or tricyclic rings such as, for example, adamantanyl.
  • the common part of a 3-8-membered saturated, partially saturated or unsaturated ring is to be understood as ring systems in which optionally one or more possible double bonds may be present in the ring, for example cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, Cyclooctenyl, where the attachment can take place both on the double bond and on the single bonds.
  • cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, Cyclooctenyl
  • Halogen is in each case fluorine, chlorine, bromine or iodine.
  • the aryl radical has in each case 6 to 12 carbon atoms, for example naphthyl, biphenyl and in particular phenyl.
  • the heteroaryl group comprises in each case 3 to 16 ring atoms and may contain one or more, identical or different, heteroatoms such as oxygen, nitrogen or sulfur in the ring instead of the carbon, and may be mono-, bi- or tricyclic, and may additionally be benzo-fused in each case ,
  • Preferred heteroaryl radicals are, for example, 5-ring heteroaromatics such as thiophene, furan, oxazole, thiazole, imidazole and benzo derivatives thereof and 6-membered heteroaromatic compounds such as pyridine, pyrimidine, triazine, quinoline, isoquinoline and benzo derivatives thereof.
  • the aryl radical comprises in each case 3 to 12 carbon atoms and may each be benzo-fused.
  • cyclopropenyl examples which may be mentioned: cyclopropenyl, cyclopentadienyl, phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, azulenyl, biphenyl, fluorenyl, anthracenyl, etc.
  • suitable salts are the physiologically tolerated salts of organic and inorganic bases, such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, 1,6-hexadiamine , Ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
  • organic and inorganic bases such as, for example, the readily soluble alkali and alkaline earth salts and N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, 1,6-hexadiamine , Ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane
  • physiologically acceptable salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid and the like.
  • the compounds of general formula I according to the invention also include the possible tautomeric forms and include the E or Z isomers or, if a chiral center is present, also the racemates and enantiomers. These include double bond isomers.
  • X and Y are the same or different and are hydrogen
  • R 19 and R 20 are identical or different and represent hydrogen, d-do-alkyl, C 2 -C 10 -alkenyl, C 2 -C 10 -alkynyl, (COOR 14 ) - (CH 2 ) n -, (C 3 - C 6 -cycloalkyl) -dC 4 -alkylene, C 3 -C 6 -cycloalkyl, phenylsulfonyl, phenyl-C 3 -C 6 -cycloalkyl, C 1 -C 10 -alkanoyl, C 1 -C 6 -alkoxy-dC 6 -alkylene, dC -
  • C 6 alkyl C 3 -C 6 cycloalkyl, halo-Ci- C 6 alkyl, halo-dC 6 alkoxy, halogen, cyano, hydroxy, C ⁇ -C 6- alkylene, hydroxy-dC 6 -alkylenoxy, aryl, heteroaryl, heterocyclyl, -C 1 -C 6 -alkyl-COOR 8 or with the group -OR 10 , -COR 13 , -COOR 14 , -NR 11 R 12 ,
  • R 19 and R 20 are each independently, together form a 3 to 10 membered ring, which may optionally contain one or more nitrogen, oxygen or sulfur atoms,
  • A is optionally substituted aryl, heteroaryl or
  • Heterocyclyl, R 22 is hydrogen, hydroxy-C 6 -C 6 alkyl, or the group
  • R 23 is hydrogen or CC 6 -alkyl
  • R 24 is hydrogen, phenyl, C 1 -C 6 alkoxy or the group
  • R 25 represents the group -OR 10 or optionally monosubstituted or polysubstituted, identically or differently with halogen, C 6 - alkyl, hydroxy-C ⁇ -C 6 alkyl or the group - OR 10 or -COOR 14 substituted C 2 -C 6 alkenyl, phenyl, pyridyl, Imidazoiyl, morpholinyl, piperidinyl, C 3 -C 6 - cycloalkyl or
  • each of m, p, k, independently of one another, is 0 or 1
  • n is 0, 1
  • q is 1 or 2 , as well as their stereoisomers
  • Selected compounds are those compounds of the general formula I in which
  • X and Y are the same or different and are hydrogen
  • Hydroxy-dC 4 alkylene, C ⁇ -C 6 -alkoxy-C ⁇ -C 6 alkylene or the group -C 1 -C 6 alkyl-O-Si (phenyl) 2 -C 1 -C 6 -alkyl, R 2 and R 3 are the same or different and are hydrogen, C 1 -C 6 -alkyl, hydroxy-C 4 -alkylene, cyclohexyl or for the
  • C 6 alkyl C 3 -C 6 cycloalkyl, halo-dC ß alkyl, halo-dC 6 alkoxy, halogen, cyano, triazolyl, tetrazolyl, hydroxy -C 1 -C 6 -alkylene, hydroxy-C 1 -C 6 -alkyleneoxy, morpholino, -CC-C 1 -C 6 -alkyl-COOR 8 or with the group -OR 10 , -COR 13 , -COOR 14 , -NR 11 R 12 ,
  • R 2 and R 3 together form a piperidino or morpholino ring
  • R 4 is hydrogen, C 1 -C 6 -alkyl, halo-dC 6 -alkyl, hydroxy
  • Phenyl, benzyl, R 8 , R 11 , R 12 , R 14 , R 15 and R 16 are the same or different and represent hydrogen, d-d-alkyl, hydroxyCrCalkylene, (COOR 14 ) - (CH 2 ) n - or represents optionally substituted by halogen or by the group - CO-C 1 -C 6 -alkyl-substituted phenyl, pyridyl, pyrimidinyl, or for the group -COR 13 , -SO 2 R 18 , - (CH 2 ) n -NR 15 R 16 , - (CH 2 ) n -C (CH 3 ) q - (CH 2 ) n NR 15 R 16 or
  • R 10 is hydrogen, C 1 -C 10 -alkyl, hydroxyCrC-alkylene,
  • R 18 is d-C ⁇ o-A! kyl, hydroxy, hydroxy-C 1 -C 6 -alkyl or the group -NR 11 R 12
  • R 22 is hydrogen, hydroxy-C 1 -C 6 -alkyl, or for the
  • R 25 represents the group -OR 10 or optionally monosubstituted or polysubstituted, identically or differently with halogen, C 6 - alkyl, hydroxy-dC or 6 with alkyl group - substituted OR 10 or -COOR 14 C 2 -C 6 - Alkenyl, phenyl, pyridyl, imidazolyl, morpholinyl, piperidinyl, C 3 -C 6 cycloalkyl or
  • each of m, p, k independently of one another, is 0 or 1
  • n is 0, 1
  • q is 1 or 2 , As well as their
  • Stereoisomers mixtures of stereoisomers and their salts.
  • a pharmaceutical preparation in addition to the active ingredient for enteral or parenteral administration suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the pharmaceutical preparations may be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If appropriate, they also contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers; Salts for changing the osmotic pressure or buffer.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surfactant auxiliaries such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof and liposomes or components thereof can also be used as carrier systems.
  • tablets, dragees or capsules with talc and / or hydrocarbon carriers or binders such as lactose, corn or potato starch
  • talc and / or hydrocarbon carriers or binders such as lactose, corn or potato starch
  • the application can also take place in liquid form, for example as juice, which may be accompanied by a sweetener.
  • enteral, parenteral and oral applications are also the subject of the present invention.
  • the dosage of the active ingredients may vary depending on the route of administration, the age and weight of the patient, the nature and severity of the disease being treated, and the like
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, which dose may be given as a single dose to be administered once or divided into 2 or more daily doses.
  • autoimmune psoriasis alopecia and multiple sclerosis
  • cardiovascular diseases stenosis, arteriosclerosis and restenosis
  • unicellular parasite infectious diseases glomerulonephritis
  • neuropathic diseases Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia, and chronic neurodegenerative diseases Alzheimer's disease, acute neurodegenerative diseases brain ischemia and neurotrauma, and viral infections
  • Cytomegalus infections herpes, hepatitis B or C, and HIV disorders are to be understood.
  • medicaments for the treatment of the abovementioned disorders which contain at least one compound according to the general formula I, as well as medicaments with suitable formulation and carrier substances.
  • the compounds of the general formula I according to the invention are, inter alia, excellent inhibitors of the polo-like kinases, such as Plk1, Plk2, Plk3 and Plk4.
  • Crystallization, chromatography or salt formation in the isomers, such as. B. are separated into the enantiomers, diastereomers or E / Z isomers, provided that the isomers are not in equilibrium with each other.
  • the preparation of the salts is carried out in a customary manner by adding a solution of the compound of formula I with the equivalent amount or an excess of a base or acid, optionally in solution, and separating the precipitate or working up the solution in a conventional manner.
  • Solvents e.g. Tetrahydrofuran, at temperatures between -20 ° C and + 50 ° C instead.
  • the intermediates of the general formula II are known from the
  • the compounds of general formula I according to the invention are prepared by addition of amines.
  • This reaction can be carried out in any suitable organic solvent, e.g.
  • Acetone, alcohols, dialkyl ethers, alkanes or cycloalkanes carried out.
  • Solvents are carried out.
  • the reaction temperatures are usually between -20 ° C and + 80 ° C.
  • the introduced amines may be primary or secondary.
  • the compounds of the general formula I according to the invention can also be prepared directly from the intermediates of the general formula III become.
  • the amine is already added in the reaction with CH (OZ) 3 , wherein Z has the meaning given in the general formula II.
  • These reactions are usually carried out at temperatures between 80-220 ° C.
  • R 2 or R 3 in the compounds of the general formula I is initially hydrogen, this radical can be carried out by reaction with optionally substituted alkanoyl halides, arylalkanoyl halides, alkoxyalkanoyl halides, aryloxyalkanoyl, alkyl halides, isocyanates, isothiocyanates, alkyl- or arylsulfonyl chlorides, optionally via parallel syntheses.
  • the present invention thus also provides compounds of the general formulas II and III,
  • process variant B 126 mg of product are obtained from 150 mg of the substance described under example c), 0.056 ml of piperidine in 2 ml of acetone.
  • process variant B 148 mg of product are obtained from 150 mg of the substance described under example c), 0.065 ml of cyclohexylamine in 2 ml of acetone.
  • process variant B 156 mg of product are obtained from 150 mg of the substance described under example c), 0.045 ml of N-methylethanolamine in 2 ml of acetone.
  • process variant B 124 mg of product are obtained from 150 mg of the substance described under Example i), 0.06 ml of aniline in 2 ml of acetone.
  • process variant B from 150 mg of the substance described under example i), 0.058 ml of morpholine in 2 ml of acetone, 138 mg of product are obtained.
  • process variant B 15 mg of product are obtained from 150 mg of the substance described under Example i), 82 mg of 4-aminoanisole in 2 ml of acetone.
  • process variant B 140 mg of product are obtained from 150 mg of the substance described under Example i), 110 mg of ethyl 4-aminobenzoate 2 ml of acetone.
  • Example 13 Analogously to Example 13, the following compounds are prepared from the intermediate product described under Example e):
  • Example 129 Analogously to Example 129), the following examples 130), 131), 132), 133) and 134) are prepared from the compounds described under Example 124), 125), 126), 127) and 128):
  • Example 139 is prepared analogously to the compound described under Example 138).
  • Example 189 Analogously to Example 189), from 60 mg of the compound described under Example a), 45 ⁇ l of triethylamine and 16 mg of methanesulfonyl chloride, after purification by chromatography on silica gel, 35 mg of the title compound are obtained as a pH-dependent 5- (E / Z) isomer mixture.
  • Example 193 Example 193
  • Example 189 Analogously to Example 189), 60 mg of the compound described under Example a), 45 ⁇ l of triethylamine and 20 mg of N, N-dimethylamidosulfonyl chloride, after purification by chromatography on silica gel, give 15 mg of the title compound as a pH-dependent 5- (E / Z) Isomer mixture obtained.
  • Example 197 Analogously to Example 197), from 100 mg of the compound described under Example 24), 0.04 ml of triethylamine, 93 mg of TBTU and 39 ul 4- (2-aminoethyl) morpholine, after purification by chromatography on silica gel 26 mg of the title compound as the pH dependent 5- (E / Z) -isomerengemisch obtained.
  • Example 197 Analogously to Example 197), from 100 mg of the compound described under Example 25), 0.04 ml of triethylamine, 93 mg of TBTU and 39 ul 4- (2-aminoethyl) morpholine, after purification by chromatography on silica gel 84 mg of the title compound as the pH dependent 5- (E / Z) -isomerengemisch obtained.
  • Example 160 Analogously to Example 160, the following compounds are prepared from the intermediate product described under Example c):
  • Example 178 Analogously to Example 178, the following compounds are prepared from the intermediate described under Example ba):
  • Example 481 (E or Z) -cyano- [5 - ( ⁇ 4- [2- (2-dimethylamino-1, 1-dimethyl-ethylcarbamoyl) -ethyl] -phenylamino ⁇ -methylene) -3-ethyl-4-oxo -thiazolidin-2-ylidene] - ethyl acetate
  • process variant B 111 mg of product are obtained from 98 mg of the substance described under example c) and 68.7 mg of 3- (4-aminobenzoylamino) -propionic acid.
  • process variant B 81 mg of product are obtained from 98 mg of the substance described under example c) and 43.6 mg of 1H-indol-6-ylamine.
  • process variant B 88 mg of product are obtained from 98 mg of the substance described under example c) and 46.0 mg of 5-amino-2-methoxy-phenol.
  • process variant B 90 mg of product are obtained from 98 mg of the substance described under example c) and 56.8 mg of 4-bromoaniline.
  • process variant B 108 mg of product are obtained from 98.0 mg of the substance described under example c) and 58.0 mg of 4-amino-N-methylphthalimide.
  • process variant B 95.0 mg of product are obtained from 98.0 mg of the substance described under example c) and 32.4 mg of 3-amino-5-methyl-1, 2,4-triazole.
  • process variant B 101 mg of product are obtained from 98.0 mg of the substance described under example c) and 43.9 mg of 5-aminoindazole.
  • process variant B from 148.2 mg of the substance described under example c) and 146.5 mg of 7-aminoindazole 64.0 mg of product are obtained.
  • Example 716 Analogously to Example 716, 89.7 mg of the substance described under Example 715 and 21.7 ⁇ l of phenyl isocyanate give 92.0 mg of product.
  • Example 719 Analogously to Example 716, 85.0 mg of product are obtained from 89.7 mg of the substance described under Example 715 and 17.4 ⁇ l of methoxymethyl isocyanate.
  • 1 H NMR (DMSO-d6, stored over K 2 C0 3 , major isomer): ⁇ 1.24 (3H), 1.26 (3H), 3.18 (3H), 3.82 (2H), 4.16-4.29 (4H), 4.50 ( 2H), 6.91 (1H), 7.09 (2H), 7.18 (2H), 7.24 (2H), 7.32 (2H), 8.16 (1H), 8.56 (1H), 10.52 (1H) ppm.
  • Example 719 Example 719
  • Example 716 Analogously to Example 716, 89.7 mg of the substance described under Example 715 and 24.0 ⁇ l of phenyl isothiocyanate give 91.0 mg of product.
  • Example 721 Analogously to Example 716, from 89.7 mg of the substance described under Example 715 and 23.0 ⁇ l of isocyanatoacetic acid ethyl ester, 106 mg of product are obtained.
  • 1 H-NMR (DMSO-d6, stored over K 2 CO 3 , main isomer): ⁇ 1.24 (6H), 1.26 (3H), 3.78-3.89 (4H), 4.10 (2H), 4.17-4.30 (4H), 6.39 (1H), 7.07 (2H), 7.18 (2H), 7.24 (2H), 7.30 (2H), 8.17 (1H), 8.71 (1H), 10.51 (1H) ppm.
  • Example 721 Example 721
  • Example 721 Analogously to Example 721, 47.3 mg of product are obtained from 60 mg of the acid described under Example xx) and 22.6 mg of 3-picolylamine.
  • Example 721 34.1 mg of product are obtained from 60 mg of the acid described under Example xx) and 26.2 mg of 1- (3-aminopropyl) imidazole.
  • Example 721 Analogously to Example 721, 122.3 mg of product are obtained from 100 mg of the acid described under Example xx) and 43.6 mg of 4-fluorobenzylamine.
  • Example 721 Analogously to Example 721, from 60 mg of the acid described under Example xx) and 30.1 mg of 4- (3-aminopropyl) -morpholine 34.9 mg of product.
  • Example 721 Analogously to Example 721, 37.2 mg of product are obtained from 60 mg of the acid described under Example xx) and 37.2 mg of 4- (2-aminoethyl) morpholine.
  • Example 721 Analogously to Example 721, 36.7 mg of product are obtained from 60 mg of the acid described under Example xx) and 29.6 mg of 1- (3-aminopropyl) -2-pyrrolidinone.
  • Example 721 Analogously to Example 721, 24.4 mg of product are obtained from 60 mg of the acid described under Example xx) and 21.1 mg of cyclohexylamine.
  • Example 721 Analogously to Example 721, 41.2 mg of product are obtained from 60 mg of the acid described under Example xx) and 36.0 mg of ethyl 4-aminopiperidine-1-carboxylate.
  • Example 721 Analogously to Example 721, 61.6 mg of product are obtained from 100 mg of the acid described under Example xx) and 26.2 mg of 3-amino-1-propanol.
  • Example 721 Analogously to Example 721, 35.7 mg of product are obtained from 80.0 mg of the acid described under Example xx) and 38.3 mg of 4-methoxybenzylamine.
  • Example 721 Analogously to Example 721, from 80.0 mg of the acid described under Example xx) and 38.3 mg of 2- (4-hydroxyphenyl) ethylamine, 19.4 mg of product are obtained.
  • Example 721 Analogously to Example 721, 65.3 mg of product are obtained from 80.0 mg of the acid described under Example xx) and 16.0 mg of allylamine.
  • Example 721 Analogously to Example 721, 15.0 mg of product are obtained from 80.0 mg of the acid described under Example xx) and 17.1 mg of ethanolamine.
  • H NMR (DMSO-d6, stored over K 2 CO 3 , major isomer): ⁇ 1.22 (3H), 3.25 (2H), 3.46 (2H), 4.21 (2H), 4.73 (1H), 7.00 (1H) , 7.10 - 7.39 (5H), 8.16 (1H), 10.32 (1H) ppm.
  • Example 721 Analogously to Example 721, 57.9 mg of product are obtained from 80.0 mg of the acid described under Example xx) and 24.9 mg of 4-amino-1-butanol.
  • Example 721 Analogously to Example 721, 10.7 mg of product are obtained from 80.0 mg of the acid described under Example xx) and 32.7 mg of 4-amino-1-hexanol.
  • Example 721 Analogously to Example 721, from 100 mg of the acid described under Example xx) and 0.1 ml of a ca. 7M solution of ammonia in methanol, 73.1 mg of product are obtained.
  • Example 721 Analogously to Example 721, 200 mg of the acid described under Example xx) and 0.35 ml of a 2M solution of ethylamine in THF give 144 mg of product.
  • Example 739 Analogously to Example 739, 59.6 mg of product are obtained from 100 mg of the acid described under Example xx) and 66.0 ⁇ l of diethylene glycol.
  • Example 739 Analogously to Example 739, 17.9 mg of product are obtained from 100 mg of the acid described under Example xx) and 139 ⁇ l of triethanolamine.
  • Example 739 Analogously to Example 739, 47.1 mg of product are obtained from 100 mg of the acid described under Example xx) and 86.9 mg of 4-hydroxybenzyl alcohol.
  • Example 739 Analogously to Example 739, from 100 mg of the acid described under Example xx) and 106.5 mg of 3- (4-hydroxyphenyl) propanol, 51.3 mg of product are obtained.
  • 1 H-NMR (DMSO-d6, stored over K 2 CO 3 , major isomer): ⁇ 1.31 (3H), 1.73 (2H), 2.64 (2H), 3.43 (2H), 4.32 (2H), 4.49 (1H ), 7.07 - 7.16 (3H), 7.26 (2H), 7.30 - 7.43 (4H), 8.21 - 8.30 (1H), 10.60 - 10.70 (1H) ppm.
  • Example 739 Analogously to Example 739, 39.4 mg of product are obtained from 100 mg of the acid described under Example xx) and 96.7 mg of 1,4-benzenedimethanol.
  • Example 739 Analogously to Example 739, 32.0 mg of product are obtained from 100 mg of the acid described under Example xx) and 83.7 ⁇ l of 2- (hydroxyphenyl) ethanol.
  • Example e Analogously to Example a), 8.5 g of product are obtained from 6 g of diethyl malonate, 5.7 ml of triethylamine and 4.9 ml of ethyl isothiocyanate.
  • Example e
  • Example b Analogously to Example b), 10.2 g of product are obtained from 12.5 g of the substance described under Example d) and 5 ml of bromoacetyl chloride in tetrahydrofuran.
  • Example g Analogously to Example c) are obtained from 1, 8 g of the compound described in Example e), 2.5 ml of triethyl orthoformate and 3.5 ml of acetic anhydride 1, 3 g of product.
  • 1 H-NMR (CDCl 3 ): ⁇ 1, 15-1, 40 (12H); 3.75 (2H); 4.20-4.45 (6H); 7.75 (1H) ppm.
  • Example j Analogously to Example c), 3.4 g of the compound described under Example h), 6.9 ml of triethyl orthoformate and 9.6 ml of acetic anhydride are used to obtain 3.4 g of product.
  • 1 H-NMR (CDCl 3 ): ⁇ 1, 31 (3H); 1.39 (3H); 4,18-4,35 (4H); 7.81 (1H) ppm.
  • Example j
  • Example a Analogously to Example a), 3.5 g of product are obtained from 3.5 g of propyl cyanoacetate, 3.5 ml of triethylamine and 2.55 ml of ethyl isothiocyanate.
  • Example n Analogously to Example a), from 4 g of isopropyl cyanoacetate, 4 ml of triethylamine and 3 ml of ethyl isothiocyanate, 6.7 g of product are obtained.
  • Example n Analogously to Example a), from 4 g of isopropyl cyanoacetate, 4 ml of triethylamine and 3 ml of ethyl isothiocyanate, 6.7 g of product are obtained.
  • Example n Analogously to Example a), from 4 g of isopropyl cyanoacetate, 4 ml of triethylamine and 3 ml of ethyl isothiocyanate, 6.7 g of product are obtained.
  • Example p Analogously to Example c) are obtained from 2 g of the compound described under 2), 3 ml of triethyl orthoformate and 4.3 ml of acetic anhydride 1, 77 g of product.
  • 1 H-NMR (CDCl 3): ⁇ 1.25 to 1, 45 (12H); 4.23 (2H); 4.37 (2H); 5.12 (1H); 7.70 (1H) ppm.
  • Example p
  • Example c Analogously to Example c) are obtained from 1.77 g of the compound described under 2), 2.83 ml of triethyl orthoformate and 4.05 ml of acetic anhydride 1.65 g of product.
  • Example a Analogously to Example a) from 2.7 g of ethyl cyanoacetate, 4.3 ml of triethylamine and 3.0 g of the compound described under Example to) after Purification by chromatography on silica gel (dichloromethane / methanol 80:20) to give 2.6 g of the title compound.
  • Example b Analogously to Example b), from 2.0 g of the compound described under Example ao), and 1.1 ml of bromoacetyl chloride in tetrahydrofuran, after recrystallization from ethanol, 340 mg of the title compound are obtained.
  • 1 H-NMR (CDCl 3 ): ⁇ 1.35 (3H); 1, 70-1, 95 (2H); 2.40-2.52 (2H); 2.70-2.90 (2H); 3.65 (2H); 4.30 (2H); 5.10 (1H) ppm.
  • Example ar Analogously to Example c), 434 g of the title compound are obtained from 450 mg of the compound described under Example ap), 0.66 ml of triethyl orthoformate and 0.93 ml of acetic anhydride after recrystallization from ethanol.
  • 1 H NMR (CDCl 3): ⁇ 1.30-1, 45 (6H); 1, 70-1.98 (2H); 2.35-2.52 (2H); 2.80-3.00 (2H); 4,15-4,38 (4H); 5.20 (1H); 7.65 (1H) ppm.
  • Example ar
  • Example 225 Analogously to Example 225), 750 mg of the compound described under Example ar), 700 mg of potassium carbonate and 480 mg of 1-tert-butyloxycarbonylpiperazine in 50 ml of DMF, after purification by chromatography on silica gel 680 mg of the title compound as a pH-dependent 5- (E. / Z) -isomerengemisch.
  • Example c Analogously to Example c), from 6.22 g of the compound described under Example yb), 9.61 ml of triethyl orthoformate and 13.46 ml of acetic anhydride, after stirring with diethyl ether, 4.22 g of product are obtained.
  • 1 H-NMR (CDCl 3 ): ⁇ 1.10 (2H), 1.37 (6H), 1.90 (2H), 3.12 (1H), 4.21 (2H), 4.31 (2H), 7.65 (1H) ppm.
  • Example 45 Analogously to Example a), from 1.0 g of the compound described under Example 459), 817 mg of triphenylphosphine, 267 mg of imidazole and 793 mg of iodine are purified after purification by chromatography on silica gel 1 .06 g of the title compound as a pH-dependent 5- (E / Z) -Isomerengemisch.
  • Example bb 89 mg of the compound described in Example bb) are dissolved in 4 ml of butanone and treated with 130 ml of potassium carbonate, 35 mg of tetrabutylammonium iodide and 100 ul of 4- (3-chloro-propyl) -morpholine and stirred for 4 hours under reflux. After aqueous work-up and purification by chromatography on silica gel, 160 mg of the title compound are obtained.
  • Recombinant human Plk-1 (6xHis) was purified from baculovirus-infected insect cells (Hi5).
  • 10 ng (recombinantly prepared, purified) PLK enzyme is incubated for 90 min at room temperature with biotinylated casein and 33P-D-ATP as substrate in a volume of 15 .mu.l in 384well Greiner Small Volume microtiter plates (final concentrations in the buffer: 660 ng / ml PLK 0.7 ⁇ M casein, 0.5 ⁇ M ATP including 400 nCi / ml 33P- ⁇ -ATP, 10 mM MgCl 2, 1 mM MnCI 2, 0.01% NP40, 1 mM DTT, protease inhibitors, 0.1 mM Na 2 VO 3 in 50 mM HEPES pH 7.5).
  • Cultured human MaTu breast tumor cells were plated at a density of 5000 cells / measuring point in a 96-well multititer plate in 200 ⁇ l of the appropriate growth medium. After 24 hours, the cells of one plate (zero point plate) were stained with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 ⁇ l) containing the test substances at various concentrations (0 ⁇ M and in the range 0.01 - 30 ⁇ M, the final concentration of the solvent dimethylsulfoxide was 0.5%) were added replaced. The cells were incubated for 4 days in the presence of the test substances. Cell proliferation was determined by staining the cells with crystal violet.
  • Fig. 1 shows the function of Pik -1
  • Pik-1 activates CDC25 C. This activates the CDK / cyclin B complex and transfers the cell from G2 to M-status.
  • PIkl plays an important role during cytokinesis, especially in the formation of bipolar spindle apparatus and chromosome separation during the late mitosis phase. Plk-1 is also needed during centrosome maturation and binds to so-called 'kinesin engines'.
  • Plk-1 activates the APC / C complex (anaphase-promoting complex / cyclosome; Kotani et al., 1998;).
  • APC / C as E3 enzyme catalyzes the polyubiquitination of specific substrates, e.g. Cyclin B Such ubiquitination of proteins ultimately leads to their degradation in the

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des thiazolidones de la formule générale (I) où R<1>, R<2>, R<3>, X et Y ont les significations données dans la description et où . représente une liaison double E ou Z. L'invention concerne également leur production et leur utilisation comme inhibiteurs de la kinase de type polo (PLK) pour traiter différentes maladies ainsi que des produits intermédiaires destinés à la production des thiazolidones.
EP03718796A 2002-05-03 2003-04-29 Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo Withdrawn EP1501794A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10221104 2002-05-03
DE10221104 2002-05-03
PCT/EP2003/004450 WO2003093249A1 (fr) 2002-05-03 2003-04-29 Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo

Publications (1)

Publication Number Publication Date
EP1501794A1 true EP1501794A1 (fr) 2005-02-02

Family

ID=29285317

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03718796A Withdrawn EP1501794A1 (fr) 2002-05-03 2003-04-29 Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo

Country Status (21)

Country Link
US (1) US20060079503A1 (fr)
EP (1) EP1501794A1 (fr)
JP (1) JP2005538048A (fr)
KR (1) KR20040106451A (fr)
CN (1) CN1649853A (fr)
AR (1) AR040074A1 (fr)
AU (1) AU2003222845A1 (fr)
BR (1) BR0309758A (fr)
CA (1) CA2484597A1 (fr)
EC (1) ECSP045476A (fr)
HR (1) HRP20041142A2 (fr)
IL (1) IL164651A0 (fr)
MX (1) MXPA04010169A (fr)
NO (1) NO20045281L (fr)
PE (1) PE20040589A1 (fr)
PL (1) PL372890A1 (fr)
RS (1) RS95404A (fr)
RU (1) RU2004135533A (fr)
TW (1) TW200406392A (fr)
WO (1) WO2003093249A1 (fr)
ZA (1) ZA200409796B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10351744A1 (de) 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
EP1632493A1 (fr) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102004061503A1 (de) * 2004-12-15 2006-06-29 Schering Ag Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
WO2006063806A1 (fr) * 2004-12-15 2006-06-22 Bayer Schering Pharma Aktiengesellschaft Thiazolidinones metasubstituees, leur production et leur utilisation en tant que medicaments
CA2590939C (fr) * 2004-12-17 2011-10-18 Amgen Inc. Composes d'aminopyrimidine et procedes d'utilisation correspondants
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005020104A1 (de) * 2005-04-25 2006-10-26 Schering Ag Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel
DE102005020105A1 (de) * 2005-04-25 2006-10-26 Schering Ag Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
EP1989330A4 (fr) * 2006-01-31 2009-10-21 Elan Pharm Inc Alpha-synucléine kinase
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
EP2124562B1 (fr) 2007-03-09 2016-04-20 Second Genome, Inc. Composés de bicyclohétéroaryle utilisés comme modulateurs de p2x7 et leurs utilisations
WO2009019205A1 (fr) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Forme cristalline d'un dérivé de dihydroptéridione
EP2247748A2 (fr) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synucléine kinase
EP2100894A1 (fr) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
EP2141163A1 (fr) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Thiazolidinone substituée, sa fabrication et son utilisation en tant que médicament
CA2745596A1 (fr) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
CN101780074B (zh) * 2010-03-02 2011-11-16 山东大学 一种抗肺癌的药物组合物
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
WO2014069434A1 (fr) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 Nouveau dérivé thiazolidinone
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
RU2546006C1 (ru) * 2014-03-07 2015-04-10 Римма Ильинична Ашкинази Противовирусное средство
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10080728B2 (en) 2015-01-20 2018-09-25 Viktor Veniaminovich Tets Hemostatic agent
WO2018217743A1 (fr) 2017-05-24 2018-11-29 Viktor Veniaminovich Tets Compositions antimicrobiennes fractionnées et leur utilisation
CN113788814B (zh) * 2021-10-15 2022-07-01 云南省烟草质量监督检测站 稻瘟灵含量检测用半抗原、制备方法及其应用
CN114380976B (zh) * 2022-01-13 2024-02-06 西安恩诺维新石油技术有限公司 一种油田用缓释型荧光示踪覆膜支撑剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6016989A (ja) * 1983-07-06 1985-01-28 Shionogi & Co Ltd オキソ飽和異項環カルボンアミドセフエム化合物
MXPA01012442A (es) * 1999-06-03 2004-09-10 Abbott Gmbh & Co Kg Compuestos de benzotiazinona y benzoxazinona.
US6291496B1 (en) * 1999-12-27 2001-09-18 Andrew J. Dannenberg Treating cancers associated with overexpression of class I family of receptor tyrosine kinases
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03093249A1 *

Also Published As

Publication number Publication date
JP2005538048A (ja) 2005-12-15
CN1649853A (zh) 2005-08-03
AU2003222845A1 (en) 2003-11-17
RU2004135533A (ru) 2005-07-20
WO2003093249A1 (fr) 2003-11-13
AR040074A1 (es) 2005-03-16
NO20045281L (no) 2005-02-01
KR20040106451A (ko) 2004-12-17
CA2484597A1 (fr) 2003-11-13
PL372890A1 (en) 2005-08-08
BR0309758A (pt) 2005-02-15
PE20040589A1 (es) 2004-11-21
RS95404A (en) 2006-10-27
TW200406392A (en) 2004-05-01
MXPA04010169A (es) 2005-02-03
HRP20041142A2 (en) 2005-10-31
ECSP045476A (es) 2005-01-28
IL164651A0 (en) 2005-12-18
ZA200409796B (fr) 2006-06-28
US20060079503A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2003093249A1 (fr) Thiazolidinones et leur utilisation comme inhibiteurs de kinase de type polo
DE69833223T2 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen
DE69533174T2 (de) Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten
US7514441B2 (en) Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents
EP1824834A1 (fr) Thiazolidinones metasubstituees, leur production et leur utilisation en tant que medicaments
EP1438046A2 (fr) Derives de benzamide de thiazole et compositions pharmaceutiques inhibant la proliferation cellulaire, et methodes d&#39;utilisation
WO2006082107A1 (fr) Thiazolidinones en tant qu&#39;inhibiteurs de la polo-like kinase (plk)
EP0352581A2 (fr) Dérivés d&#39;éthylènediamine monoamide
DE10351744A1 (de) Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US6083959A (en) Quinoline derivatives, processes for their preparation and their use as medicaments
US4921887A (en) Thiazole compounds and pharmaceutical composition comprising the same
EP0409048A2 (fr) 2-Aminothiazoles substitués par un aminoalcoyle et médicaments les contenant
DE4129742A1 (de) Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
DE60318584T2 (de) Arylimidazolderivate und deren verwendung als no-synthase-inhibitoren und als modulatoren der na-kanäle
EP0124630B1 (fr) Dérivés de pyrimidinothioalkyle pyridine, procédé pour leur préparation et médicaments contenant ces composés
DE102004061503A1 (de) Metasubstituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
EP1732901B1 (fr) Composes imidazole a substitution 4-aminocarbonylamino a activite antivirale
EP0110298B1 (fr) Dérivés d&#39;acridanone
EP0298040B1 (fr) Dérivés de 1,3-dithiol-2-ylidène
EP0302164A1 (fr) Esters d&#39;acides guanidinecarboxyliques, procédés pour leur préparation et médicaments contenant ces composés
EP0180754A2 (fr) Dérivés de 3,4-diazole, procédé pour leur préparation et médicaments contenant ces composés
DE60318459T2 (de) Neue verbindungen
DE4119755A1 (de) Aminoalkylsubstituierte 2-amino-1,3,4-thiadiazole, ihre herstellung und verwendung
MXPA06004918A (en) Thiozolidinones, production and use thereof as medicaments
EP0737680A1 (fr) Composés de (phénylalkylaminoalkyloxy)-hétéro-aryle, procédés et produits intermédiaires pour leur préparation et médicaments contenant ces composés

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

17Q First examination report despatched

Effective date: 20060516

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111101